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HR Hazard ratio 
HRPZ II Hospital Raja Perempuan Zainab II 
HSB Hospital Sungai Buloh 
HUSM Hospital Universiti Sains Malaysia 
ID  Infectious diseases 
IRT Item response theory 
IVDU Intravenous drug used 
ll  Log likelihood 
LML Log minus log 
LN  Lymph node 
LR  Likelihood ratio 
MC Multicollinearity 
MIMIC  Multiple indicators and multiple causes 
ML Maximum likelihood 
MLMV  Maximum likelihood with missing value 
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MLogR Multiple logistic regression 
MOH Ministry of Health 
MOT Mode of HIV transmission 
NFI Normed fit index 
OLS Ordinary least square 
PLHIV People living with HIV 
PMEM  Preliminary main effect model 
PTB Pulmonary tuberculosis 
QML Quasi-maximum likelihood 
RMSEA Root mean square error of approximation 
RNA  Ribonucleic acid 
ROC  Receiver operating characteristic 
SD  Standard deviation 
SE Standard error 
SEM Structural equation modeling 
SLogR Simple logistic regression 
TB Tuberculosis 
TBC TB code 
TVC Time varying covariate 
VIF Variance inflated factor 
WHO  World health organization 
WLS Weighted least square 
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FAKTOR-FAKTOR BERKAITAN DENGAN TERAPI ANTI 
TUBERCULOSIS (ATT), HASIL RAWATAN ATT DAN 
KELANGSUNGAN HIDUP PESAKIT KO-INFEKSI TB/HIV 
MENGGUNAKAN PERMODELAN UMUM PERSAMAAN 
BERSTRUKTUR 
ABSTRAK 
Pendahuluan: Bilangan jangkitan TB/HIV yang dilaporkan di Malaysia adalah kira-
kira lapan peratus daripada keseluruhan kes HIV dan kira-kira 5.9 peratus daripada 
jumlah kes TB yang dimaklumkan. Peratusan kes telah menurun pada setiap tahun 
bermula pada tahun 2007. Untuk strategi pencegahan yang lebih berkesan, model 
TB/HIV perlu dibangunkan terutamanya yang serasi dengan keadaan di Malaysia. 
Objektif: Kajian ini telah dicadangkan untuk memodelkan jangkitan TB/HIV  
berdasarkan faktor-faktor yang berkaitan pematuhan terapi anti tuberculosis (ATT) 
dan faktor-faktor berkaitan dengan hasil rawatan TB dan juga faktor-faktor ramalan 
kematian dalam jangkitan TB/HIV dan juga untuk menilai model tersebut 
menggunakan kaedah baru yang dikenali sebagai  model umum persamaan 
berstruktur.  
Metodologi: Kajian retrospektif kohort telah mengekstrak maklumat seperti sosio-
demografi, sosial dan sejarah perubatan, tanda-tanda dan gejala-gejala semasa di 
diagnosis, dan rawatan daripada 284 rekod perubatan dari tahun 2005 hingga 2012 di 
dua buah hospital kerajaan yang terpilih. Pelbagai regresi logistik telah digunakan 
dalam dua analisis; penentukan faktor-faktor yang berkaitan dengan pematuhan ATT 
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dan faktor-faktor yang berkaitan dalam hasil rawatan ATT. Sementara itu, Cox 
regresi digunakan dalam menentukan faktor-faktor ramalan kematian. Semua hasil 
telah digabungkan bersama-sama dan pembolehubah pendam diagnosis TB 
dimasukkan untuk menentukan model jangkitan TB/HIV menggunakan model umum 
persamaan berstruktur. Kesan pengantaraan juga telah dinilai dalam model tersebut.  
Keputusan: Model ini telah mengenal pasti tiga faktor penting yang berkaitan 
pematuhan ATT (hepatitis, umur TB diagnosis dan sejarah TB sebelumnya), lima 
faktor penting yang berjaya dalam rawatan TB (kiraan CD4, kawasan kediaman, 
pematuhan ATT, tempoh ATT dan menerima HAART) dan lima faktor prognostik 
kematian (hasil ATT, MOT seksual, MOT IVDU, menerima HAART, tempoh ATT) 
termasuk satu pembolehubah yang berubah mengikutmasa (kawasan tempat tinggal). 
Pembolehubah terpendam diagnosis TB diukur dengan  simptom batuk, demam, 
berpeluh malam, kehilangan berat badan dan penemuan makmal (dada x-ray, calitan 
sputum AFB dan pengkulturan. Gabungan semua hasil analisis secara serentak oleh 
kaedah baru ini telah memberi hasil yang sama seperti kaedah tradisional dengan 
kemajuan penambahan pembolehubah terpendam. Hasil rawatan ATT telah didapati 
memberi kesan pengantara  pematuhan ATT kepada kematian.  
Kesimpulan: Kemajuan pemodelan umum  persamaan berstruktur untuk 
menganalisis banyak hasil keputusan taburan yang berlainan secara serentak dengan 
penambahan pembolehubah terpendam pada masa yang sama boleh memberi 
manfaat kepada ramai penyelidik untuk mengesahkan model mereka. Walau 
bagaimanapun, kaedah ini masih dalam pembangunan awal dan mempunyai banyak 
batasan yang perlu ditambah baik oleh pemaju perisian.  
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FACTORS ASSOCIATED WITH ANTI TUBERCULOSIS THERAPY 
(ATT) COMPLIANCE, ATT OUTCOMES AND SURVIVAL OF 
PATIENTS WITH TB/HIV CO-INFECTION USING GENERALIZED 
STRUCTURAL EQUATION MODELING (GSEM) 
ABSTRACT 
Introduction: The number of TB/HIV co-infection reported in Malaysia is about 
eight percent of total HIV cases and about 5.9 percent of total notified TB cases. The 
proportion of the cases was decreased each year started in 2007. For more effective 
strategies of preventive, a model of TB/HIV should be developed especially 
compatible with Malaysia situation.  
Objectives: This study was proposed to model TB/HIV co-infection based on 
associated factors of anti TB treatment compliance and associated factors of TB 
treatment outcome and also predictor factors of mortality in TB/HIV co-infection and 
to assess the model using a new method known as a generalized structural equation 
model.  
Methodology: Retrospective cohort study had extracted out information such as 
socio-demographic, social and medical history, signs and symptoms at diagnosis and 
treatment from 284 medical records from 2005 to 2012 in two selected government 
hospitals.  Multiple logistic regression was applied in two analyses; determination of 
associated factors in ATT compliance and associated factors in the ATT outcome. 
Meanwhile, Cox regression was used in determining predictor factors of mortality. 
All outcomes were combined together and latent variable of TB diagnosis was added 
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to determine the TB/HIV co-infection model using generalized structural equation 
modeling. The mediating effect also was assessed in the model.  
Results: The model had identified three significant associated factors of ATT 
compliance (hepatitis, age of diagnosis TB and history of previous TB), five 
significant factors of success in TB treatment (CD4 count, area of residency, ATT 
compliance, ATT duration and received HAART) and five significant predictor 
factors of mortality (ATT outcome, MOT sexual, MOT IVDU, received HAART, 
ATT duration) included one time varying covariate variable (area of residency). The 
latent TB diagnosis variable was significantly measured by symptoms of cough, 
fever, night sweating, loss of weight and laboratory findings (chest x-ray, sputum 
AFB smear and culture). The combination of all outcomes of the analyses 
simultaneously by a new method gave a similar result as traditional methods with 
advances in increments of a latent variable added. ATT outcome was suspected to 
mediate the effect of ATT compliance to mortality.  
Conclusion: Development of generalized structural equations modeling to analyze 
simultaneously many outcomes of different distributions with the addition of latent 
variables at the same time can benefit many researchers to validate their models. 
However, the method was still in early development and has many limitations need 
to improve by the software developer. 
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CHAPTER 1: 
INTRODUCTION 
 
1.1 Tuberculosis 
Tuberculosis (TB) is a disease that is caused by the bacterium Mycobacterium 
tuberculosis that primarily affects the lungs. It also can affect other parts of human 
body such as bone, brain, kidneys and spine. These are known as extra-pulmonary 
tuberculosis. Without any treatment, it can lead to serious health problems including 
death. It is spread when the air contaminated with TB bacteria from a person who has 
active TB disease to another person nearby who may breathe in these bacteria and 
become infected (CDC, 2011). 
There are two conditions of tuberculosis. A condition where the infected body can 
fight the bacteria and stop them from growth is known as latent TB infection. At this 
stage, the person does not feel sick and do not have any symptoms except a positive 
reaction to the tuberculin skin test or special TB blood test and also cannot spread TB 
bacteria to the others. The second condition is when TB bacteria becomes active in 
the body and the immune system cannot stop them from multiplying, this is called 
TB disease. The person will feel sick and also can spread the bacteria to another 
person (CDC, 2011). 
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1.2 Human Immunodeficiency Virus (HIV) 
Human Immunodeficiency Virus (HIV) is a retrovirus which infects humans when in 
contact with tissues such as those lining the vagina, anal area, mouth, eyes or through 
a break in the skin. HIV infection is a slowly progressive disease in which the virus 
is present throughout the body at all stages of the disease (Schoenfield, 2011).  
There are three stages of HIV infection. The primary infection (initial stage) occurs 
within weeks of acquiring the virus and a symptom is characterized by a flu or mono- 
like illness that generally resolves within weeks. A chronic asymptomatic infection 
stage is a duration of infection without symptoms in an average of eight to 10 years. 
Lastly, the stage of symptomatic infection occurs when the defense system has been 
suppressed and complications have developed (AIDS stage). The symptoms are one 
or more unusual infections or cancers, severe loss of weight and dementia 
(Schoenfield, 2011). 
1.3 TB/HIV co-infection 
The breakdown of the body immune system is the hallmark of HIV infection. This 
makes HIV/AIDS patients susceptible to a variety of opportunistic infections (Walia, 
2002). Tuberculosis is one of the most important and the commonest life threatening 
and opportunistic infections in HIV infected patients, since the pandemic of AIDS 
(Iyawoo, 2004; Narain & Lo, 2004; Lawn, 2005). Meanwhile, HIV is also emerging 
as the strongest known risk factor for the development of TB (Lawn, 2005) and the 
progression to active TB among those infected both with TB and HIV (Narain & Lo, 
2004).  
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In most cases, tuberculosis infection comes first and HIV is contracted subsequently 
when the person achieves adolescence or adulthood. Once co-infected, the 
progression to active TB occurs quite rapidly (Narain & Lo, 2004). 
HIV critically impairs cell-mediated host responses to M. tuberculosis. Numeric 
depletion of M. tuberculosis-specific CD4 lymphocytes and functional impairment of 
CD4 lymphocyte–macrophage interactions result in the impaired granuloma 
formation, ultimately leading to failure to restrict M. tuberculosis replication. A 
spectrum of histological appearances is seen; increasing immunodeficiency is 
associated with progressive failures of granuloma formation and increasing 
mycobacterial burden. The interaction between TB and HIV is bidirectional. 
Activation of mononuclear cells during the host response to TB leads to accelerated 
HIV replication, which may increase HIV load at anatomical sites involved with TB 
and systemically (Lawn, 2005). 
Underlying HIV infection may alter the pathogenesis and clinical presentation of TB. 
The diagnosis of TB in patients with HIV is more difficult for the following reason 
as stated by; Sensitivity and reliability of tuberculin test get reduced since HIV 
infection causes depression of cell-mediated immunity. Only 30% to 50% of co-
infected patients have a positive result. Therefore, full diagnostic evaluation should 
be undertaken in all patients who have clinical features compatible with TB; in HIV 
infected patients with pulmonary tuberculosis, sputum culture is positive for acid fast 
bacillus in about 90% of cases and by smear in about 50% to 70% similar to results 
seen in immunocompetent adults with reactivation TB and; chest X-ray 
abnormalities are even more non-specific in HIV infected patients than in HIV 
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negative patients, which may result in under diagnosis. Radiological patterns depend 
on the level of immunity in the host. Typical pulmonary lesions are seen only in 
about one-third of the HIV infected patients with clinical TB (Walia, 2002). 
The aim of this study was focused on anti tuberculosis therapy (ATT) which include 
the factors of compliance on ATT, factors of success in ATT and survival in TB/HIV 
co-infection patients. 
1.3.1 ATT compliance 
The principles of tuberculosis treatment in HIV-infected individuals are the same as 
those in HIV-negative individuals which involved intensive and maintenance phases. 
The regimen that used in this two phases also same in both group. However, for 
patients who iniated anti-retrovirus therapy (ART) during TB treatment, a few 
factors may need to concern such as drug-drug interactions, high pill burden, 
overlapping drug toxicities, and immune reconstitution inflammatory syndrome 
(IRIS) (Bekker & Wood, 2011). 
The compliance factors between this two groups may differ due to specific issues 
including regimen length and schedule of administration of antituberculosis drugs, 
timing and drug combinations of antiretroviral drugs, overlapping toxic effects, drug 
interactions, and occurrence of immune reconstitution in TB/HIV patients (Blanc et. 
al., 2007)  
ATT compliance was defined as the extent to which the patient’s behaviour matched 
the prescriber’s recommendations (Robert Horne et. al, 2005). Meanwhile, non-
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compliance which also well known as defaulted was defined as interruption of the 
treatment for two consecutive months or more (WHO, 2012). 
Factors of compliance to ATT have been done in many studies in the world. 
Generally, the factors can be associated with the individual, disease and medication 
and also health services (Neves, 2010). 
1.3.2 ATT outcomes 
The main aim of every treatment is to cure or success in the treatment. In anti 
tuberculosis therapy, the outcomes were divided into two groups; successful 
treatment was defined as cure (negative smear of sputum in last month of treatment 
and on at least one previous occasion for a patient who was initially sputum smear 
positive) or completion of treatment (did not meet the criteria for cure or failure for a 
patient who completed treatment) and unsuccessful treatment was treatment default 
(interruption treatment for two or more consecutive months), death (died from any 
cause before treatment completed) or treatment failure (sputum smear remained 
positive at month five or later for a patient who initially sputum smear positive) 
(WHO, 2012). 
Same as ATT compliance, there are many factors associated with the outcomes of 
the treatment which also can be related to individual, disease and also health 
services. 
1.3.3 Survival in TB/HIV co-infection 
Cure or success in tuberculosis therapy may increase the survival of patients. WHO 
(2006) has reported that more than 25% of death among TB patients is attributable to 
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HIV co-infection and it is the primary reason of failure to achieve TB control targets 
in countries with high HIV infection. 
Many studies have determined that survival probability was lower in TB/HIV 
patients (Shaweno & Worku, 2012; Sileshi et. al., 2013; Roshanaei et. al., 2014). 
Low in survival probability means high in mortality. Many predictors related to the 
patient, disease and treatment such as compliance with the treatment (Tseng et. al., 
2007), receiving antiretroviral treatment (Manosuthi et. al., 2006) and CD4 count 
level (Sileshi et. al., 2013) were associated with this event.  
Identifying predictors of mortality is important to predict the prognosis of the disease 
in this patients and help in planning the effective interventions to reduce the 
mortality rate (Senbeta et. al., 2014), 
1.4 Concepts of the Chosen Statistical analyses  
1.4.1 Logistic regression 
Logistic regression was used to analyze a categorical dependent variable which was 
measured qualitative variable like an outcome (succeed or failed), status (lived or 
death) or stages (mild, moderate or severe). It can be in a form of dichotomous 
(binary) or polytomous variable. It recommends the best fitted model or the most 
parsimonious model to describe the relationship between a dependent variable and a 
set of independent or predictor variable which represents the conditional probability 
of experiencing the outcome given by independent variable, Pr(Y=1|x). Coefficients 
for its equation were computed by maximum likelihood estimates and a link function 
for logistic is equal to logit (Hosmer & Lemeshow, 2004): 
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𝑙𝑜𝑔𝑖𝑡{𝑃𝑟 (𝑌 = 1|𝑥)} = 𝑙𝑜𝑔 {
𝑃𝑟 (𝑌 = 1|𝑥)
1 − 𝑃𝑟(𝑌 = 1|𝑥)
} = 𝛽0 + 𝑥
′𝛽,   
where 𝛽0 is the intercept parameter and 𝛽 is the vector of slope. 
1.4.2 Survival analysis 
Survival analysis was used to measure the time to an event of the interest. It also can 
handle incompletely observed time-to-event data which was known as censored data.  
The most common form of censoring is right-censoring which occurs when the 
studied event has not occurred by the time of data collection ended. There are three 
types of this regression; nonparametric, semiparametric and fully parametric 
regression which differed in their distribution assumption of failure times (Hosmer 
et. al., 2008). 
Kaplan Meier was used for nonparametric maximum likelihood estimation of 
survival function from censored data. It is also known as a product limit estimator. 
Kaplan Meier estimate is a step function with discontinuities at observed event 
(death) times. For uncensored data, the estimation would be the empirical survival 
function (Kleinbaum & Klein, 2005). 
Semiparametric estimation of survival analysis which used in this study was 
represented by Cox proportional hazard (PH) model or also known as Cox model. It 
is a widely used method in survival analysis. The Cox model has two component in 
formula; baseline hazard function (h0(t)) and an exponential function of X’s 
explanatory variables (𝑒∑ 𝐵𝑖𝑋𝑖
𝑝
𝑖=1 ). The important assumption in this model is 
proportional hazard must be constant over time. It this assumption is violated, the 
extended Cox model may required which involved time dependent variable analysis. 
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The formula of Cox can reduces to baseline hazard if all the X’s are equal to zero or 
no X’s in the model. That baseline hazard is unspecified. This is the reason of 
semiparametric  model (Kleinbaum & Klein, 2005).  
Meanwhile, parametric survival model is a model in which the distribution of the 
outcome (survival time) is specified in terms of unknown parameters, which are 
estimated from the data. The common distribution used in this model are the 
Weibull, the exponential, the log-logistic, the lognormal and the generalized gamma. 
This parametric model no need proportional hazard model since many of the models 
are  acceleration failure time (AFT) models (Kleinbaum & Klein, 2005). 
The Cox model is widely popular compared to parametric model because it does not 
rely on distributional assumptions for the outcome. Although the baseline survival 
function is not estimated with a Cox model, Cox-adjusted survival estimates still can 
produce by computer packages such as SAS, Stata, and SPSS using a complicated 
algorithm that generalizes the Kaplan–Meier (KM) approach. An estimation of the 
baseline hazard also is not necessary for the estimation of a hazard ratio since the 
baseline hazard cancels in the calculation (Kleinbaum & Klein, 2005). 
1.4.3 Generalized Structural Equation Modeling 
In the medical field, most of the recorded data in patient’ private and confidential 
folder were in the form of statement which always contained the patient complains, 
laboratory investigations and evidence, the physician observations, planned of 
treatments, treatment effects and treatment outcomes. Even though the data was in a 
statement form, the majority of the data was interpreted as a categorical whether in 
binary, ordinal or nominal information such as signs and symptoms from the patient 
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complains which was interpreted as either yes/no or available/not available, based on 
scale for pain, classification of disease, type of treatment, type of adverse event and 
status of the outcome. Some of the data may also contain the information in 
numerical forms such as age, duration or length of treatment and value of 
investigation such as blood pressure, blood sugar or cholesterol. But this information, 
usually was interpreted as low/high or mild/severe as more meaningful interpretation 
of them in this field.  
This valuable data were observed and combined the characteristics of diseases as a 
guideline for them to diagnose the disease, to plan the treatment or to estimate the 
outcome for the future patients. In this sense, it is important to analyze, modeling and 
interpret the data of patient for them to work more conveniently with the prediction 
model. Since every data will have more than one outcome, the data should be used 
many models based on the each outcome. For them to have more accurate in every 
decision, the models should be combined together as a disease model which contains 
every important aspect of the disease characters.  
One of the available analyses that can fulfil the requirement is structural equation 
modeling. This model is built from the combination of theoretical framework and 
was tested to confirm the theory with the available data. It also can do the 
combination of many equation models simultaneously and it is suitable to build a 
disease model as a guideline. However, the model can be modified to fit the available 
data to find the best model for the management of a patient.  
Structural Equation Modeling (SEM) is a comprehensive statistical approach to 
testing hypotheses about relations among observed and latent variable. It is combined 
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the measurement model and structural model into a simultaneous statistical test 
which is valuable in inferential data analysis and hypothesis testing. Its pattern of 
interrelationships directionally or non-directionally among the study constructs are 
specified a priori and grounded in establishing the theory (Hoe, 2008). 
SEM is usually used because it permits the measurement of several variable and their 
inter-relationships simultaneously and also allows for simultaneous, multiple 
dependent relationships between variable (Hoe, 2008). The purposes of SEM are to 
understand the patterns of correlation or covariance among a set of variables and to 
explain as much of their variance as possible with the model specified (Kline, 2011). 
The hypothesized causal relationships can be tested among the theoretical construct 
to estimate and to evaluate the structural portion of the model. The raw data are used 
to generate the iterations, goodness of fit indices and standardized paths (Hoe, 2008).  
SEM method was originated for linear relation model (Joreskog, 1970). However, 
the method was modified over the time to be applied in the nonlinear structural 
model (Bollen, 1995). The extension of SEM made easier for non-normal data to be 
analyzed and interpretable. 
Rabe-Hesketh (2004a) had modified a method by a combination of SEM and 
generalized linear mixed model to represents a generalization of multilevel 
regression models or generalized linear mixed models. It is known as a generalized 
structural equation model. The advantage of this method is it does not require the 
data to be balanced in any of the three criteria; no missing items in multivariate 
responses, the same number of units at each level in multilevel design and balanced 
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covariates, which need the same sets of values for each higher-level unit in a 
balanced multilevel design. 
Before that, Muthen (1979) had developed a structural equation model that involved 
dichotomous responses latent variable which allowed the representation of the causal 
relations between responses and exogenous variable. Then, the analysis became more 
widely used as compatible with different types of data, such as continuous, ordinal or 
multinomial data with latent variable. His team also developed a software namely 
MPlus to run the SEM analysis and deal with this type of data. 
The choice of estimation in SEM has played an important role to get a correctly 
specified model. An estimation procedure such as maximum likelihood (ML), 
generalized least square (GLS) and weighted least squares (WLS) mostly will depend 
on a distribution of a data. Meanwhile, Bayesian estimation will be the chosen for a 
data with categorical responses variable. 
This new method recently was applied in a few studies. Musenge et al. (2013) in a 
study of understanding TB/HIV mortality in children had used a structural equation 
model to modeling a complex relationship of multiple exposures and the mortality of 
TB/HIV in children as an outcome.  
This approach whether structural equation modeling or its extension was also used in 
the estimation of the direct, indirect and total effects. For example,  Karpa et al. 
(2009) had used structural equation modeling and Cox regression to determine the 
associated factors of visual impairment to mortality in older people and assessed the 
direct and indirect effects that link between the pathway. Meanwhile, Christ et al. 
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(2008) had used a generalized linear structural model to estimate the direct effect of 
visual impairment on health, disability and mortality and also estimated the indirect 
effects of visual impairment on mortality through health and disability mediators. 
In time to time, many researchers have modified and developed new estimation 
methods to compatible with different types of data. Each extension of SEM has 
advantages and disadvantages. They have their owned limitations. This same goes 
into software development. Some software can analyze different types of data and 
some may be cannot do that. The common software to analyze SEM are AMOS, 
MPlus, SAS, LISREL, EQS, STATA, R and SmartPLS. 
1.5 Problem Statement and Research Gap  
Medicine is a wide field to perform applications of statistics in research. Many 
analyses can be applied in this field. One of the new methods in statistics is a 
structural equation modeling.  Applications of structural equation modeling in 
medicine are in a development phase. Majority of them were in forms of continuous 
covariates and were analyzed using a linear structural equation modeling. However, 
since much of information in medical data were in forms of categorical data such as 
signs and symptoms (Yes/No) or more meaningful if the variables were in 
categorical forms. For example, age was more meaningful if it is interpreted as 
young and old or grouping them as infants, toddlers, teenagers and adults. A classical 
approach of structural equation model has to be modified to be compatible with the 
data without any problem in the validity of the analysis. 
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Generalized structural equation modeling is one of the options that we can analyze 
this type of data. But its application especially in medicine is still new. From 
literature search, only one study had applied this method to an ophthalmology study 
using MPlus software (Christ et. al., 2008). So this study would like to apply this 
method using a new program in STATA software in TB/HIV co-infection model 
specified more on multiple regression equations involving simultaneous equations 
and latent variables with aiming it will contribute knowledge to other researchers to 
apply this method in their research. 
As a conclusion, TB/HIV co-infection is a complex disease which demands the 
application of an advanced analysis that able to link multiple causations and outcome 
clearly using a path diagram i.e GSEM. At present, not many studies had applied the 
analysis of GSEM in complicated medical data such in this disease. Hopefully, this 
study would contribute as a guideline for other medical researchers to apply this 
method in their research. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 HIV Case Definition 
WHO (2007) had published a guideline for HIV case definition. A case of HIV 
infection is defined as an individual with HIV infection irrespective of clinical stage 
(including severe or stage 4 clinical disease, also known as AIDS) confirmed by 
laboratory criteria according to country definitions and requirements. WHO provides 
a simplified HIV case definition designed for reporting surveillances. However, 
countries should develop and review their testing algorithms regularly for diagnosis 
and surveillance purposes. 
HIV infection is diagnosed based on positive HIV antibody testing (rapid or 
laboratory-based enzyme immunoassay) and confirmed by a second virological test 
obtained from a separate determination. First, clinical criteria for the diagnosis of 
advanced HIV in adults and children with confirmed HIV infection or presumptive 
or definitive diagnosis of any stage 3 or stage 4 conditions. Second, immunological 
criteria for diagnosing advanced HIV in adults and children five years or older with 
confirmed HIV infection, which is CD4 count less than 350 per mm
3
 of blood in an 
HIV-infected adult or child (WHO, 2007). 
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2.2 Tuberculosis Case Definition  
MOH (2002) had a guideline for tuberculosis case definition:  
1. Pulmonary tuberculosis: Tuberculosis involving the lung parenchyma. 
2. Pulmonary tuberculosis, smear positive: 
i. Tuberculosis in a patient with at least two initial sputum smear examinations 
(direct smear microscopy positive for acid fast bacilli (AFB). 
ii. Tuberculosis in a patient with one sputum smear examination positive for 
AFB and radiographic abnormalities consistent with active pulmonary 
tuberculosis as determined by the treating doctor. 
iii. Tuberculosis in a patient with at least one sputum smear examination 
positive for AFB and sputum culture positive for M. tuberculosis 
3. Pulmonary tuberculosis, smear negative: 
i. Tuberculosis in a patient with at least three sputum smear examinations 
negative for AFB and with radiographic abnormalities consistent with 
pulmonary tuberculosis, determined by a doctor followed by a decision to 
treat the patient with a full course of anti-tuberculosis therapy. 
ii. Tuberculosis in a patient whose initial sputum smears were negative, who 
had sputum sent for culture initially, and whose subsequence sputum culture 
result is positive for M. tuberculosis 
4. Extrapulmonary tuberculosis: Tuberculosis of organs other than the lung 
parenchyma. Diagnosis should be based on at least one culture-positive 
specimen from an extrapulmonary site or histological or strong clinical 
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evidence consistent with active extrapulmonary tuberculosis followed by a 
decision by a doctor to treat with a full course of anti-tuberculosis therapy. 
5. Pulmonary with extrapulmonary tuberculosis: Tuberculosis involving the lung 
parenchyma as well as any other part of the body. 
2.2.1 Definition of Terms in Tuberculosis Case 
1. New case: A patient who has never had treatment for tuberculosis or has 
taken anti tuberculosis drugs for less than 4 weeks duration in the past. 
2. Relapse case was divided into two categories: 
a. Sputum positive relapse: A patient who has been declared cured of 
any form of tuberculosis in the past by a doctor after one full course 
of chemotherapy and has become sputum smear positive. 
b. Sputum negative relapse: A patient who has been declared cured of 
any form of tuberculosis in the past by a doctor after one full course 
of chemotherapy and has developed active disease based on 
bacteriological, histological or clinical and radiological assessment 
3. Chronic case: A patient who remained or becomes smear positive again after 
completing a fully supervised retreatment regimen. 
4. Treatment failure: A patient who while on treatment, remained or become 
again smear positive 5 months or later after commencing treatment. It is also 
a patient who was initially smear negative before starting treatment and 
become smear positive after the second month of treatment. 
5. Treatment after interruption: A patient who interrupts anti tuberculosis 
treatment for 2 months or more, and then returns to the health service with 
17 
 
smear positive sputum. Sometimes smear negative, but still with active 
tuberculosis as judged on clinical and radiological assessment. 
6. Transferred in/out case: A patient transferred from/to another centre for 
continuation of treatment of tuberculosis. A transfer implies that the centre to 
which the patient is transferred undertakes the responsibility of continuing to 
treat the patient and supervising the progress. A patient is not considered to 
have been transferred if he/she presents at another treatment centre merely to 
obtain treatment. 
2.3 Epidemiology of TB/HIV Co-infection 
2.3.1 Global Situation 
The number of people living with HIV (PLHIV) has stated to be increased from year 
to year. In 2009, the number of PLHIV was 33.3 million (31.4 million-35.3 million). 
From there, 30.8 million (29.2 million-32.6 million) were adult, 2.5 million (1.6 
million- 3.2 million) were children below 15 years old and 15.9 million (14.8 
million- 17.2 million) were women (WHO, 2009) 
Data for people newly infected with HIV in 2009 was shown that the total was 2.6 
million (2.3 million- 2.8 million) with 2.2 million (2.0 million-2.4 million) were 
adults and 370,000 (230,000 – 510,000) were children below 15 years old (WHO, 
2009).  WHO has reported that Sub-Saharan Africa was 80% of the global burden of 
HIV associated TB in 2009. The magnitude of HIV infection is known to be greatest 
in sub-Saharan African, where as many as a third of all patients with active 
tuberculosis are HIV infected.  
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However, in other regions of the world, where the overall prevalence of tuberculosis 
is not as high as in developing countries, the interaction between the two pathogens 
may also be a substantial problem. In regions such as the Western Pacific and 
Southeast Asia, WHO data indicated that TB/HIV co-infection is much less common 
than in Africa, although it is likely that the estimates are on the lower side because of 
under reporting of HIV infection (Walia, 2002).  
The seroprevalence of HIV infection that was studied by Kassu et al. (2007) in 
northwest Ethiopia was 52.1% from the total of 257 TB patients with pulmonary TB 
and extrapulmonary TB were diagnosed in 64.2% and 35.8% of the patients, 
respectively. The study also concluded that the co-infection with HIV was high in 
patients with TB. 
2.3.2 Situation in Asia 
Asia has the largest numbers of tuberculosis cases (60% of the global total) and 8.55 
of 39.50 million in HIV seroprevalence (Vermund & Yamamoto, 2007). It also 
reported, that 40% to 70% of HIV patients had tuberculosis infection and 40% of 
persons were dying with HIV were attributable to tuberculosis co-infection. 
In mainland China, a cross sectional study was conducted through a standardized 
questionnaire was done by Jiang et al. (2008). The three year survey study from 
January 2003 to December 2005 which involved 241 eligible patients with TB/HIV 
co-infection was shown that 66.0% of the patients were co-infected with pulmonary 
TB and 14.5% were co-infected with haematogenous disseminated pulmonary TB. 
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Meanwhile, 40.7% of the total numbers of cases in the study were co-infected with 
extra-pulmonary TB. 
2.3.3 Situation in Malaysia 
In Malaysia, WHO (2011) has reported that in 2009, there were 18,102 cases of TB 
with 1,582 of death cases and the incidence rate was 63.95. The new cases were 
16,921 and 1,181 were retreatment cases.  
Data from Ministry of Health (MOH, 2012) has shown that in 2012, there were 1347 
cases of TB/HIV co-infection (5.9%) with contribution from Selangor 192 cases 
(14.3%) and Kelantan  179 cases (13.3%). Both states were the highest and the 
second highest of TB/HIV co-infection in Malaysia in 2012. In 2009, from 15,192 
(84%) TB patients who were screening for HIV, there were 1,644 TB patients who 
were infected with HIV (WHO, 2011) and the number of the cases was reduced to 
1629 in 2011 (MOH, 2012). The data showed that the number of cases was 
decreased year to year starting from 2007 (Figure 2.1).  
 
 
 
 
 
Figure 2.1: TB/HIV co-infection from 2000 to 2011 (adapted from MOH, 2012) 
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A retrospective record review study done by Nissapatorn et al. (2005) at National 
Tuberculosis Centre in Malaysia in order to compare the characteristics of HIV 
positive patients with pulmonary and extra-pulmonary tuberculosis was found that 
from a total of 252 HIV positive patients, the incidence of pulmonary tuberculosis 
(PTB) was 78.6% with 10.6% from the group was disseminated tuberculosis. 
Meanwhile, the incidence of extra-pulmonary tuberculosis (ETB) was 21.4%.  
In most cases, the clinical presentation of tuberculosis in patients with HIV is 
indistinguishable from those patients who do not have HIV infection. However, some 
HIV positive TB patients, particularly at an advanced stage of HIV may present with 
an atypical pattern, with a higher proportion of cases tending to have a negative 
sputum smear. Nonetheless, sputum smear examination remains an essential 
component in TB diagnosis, even in countries where HIV infection is common, 
because of its ability to identify infectious cases (Narain & Lo, 2004). 
From the study by Jiang et al. (2008), the clinical manifestations in the majority of 
the patients were fever (87.6%), fatigue (61.0%) and weight loss (60.2%).  
Other studies conducted by Nissapatorn et al. (2005) and Kassu et al. (2007) also 
stated that the main clinical presentations for PTB were cough, loss of appetite or / 
and loss of weight and fever. There were also significant associations between 
cough, sputum and haemoptysis (Nissapatorn et al., 2003). But when they control the 
confounder by Multiple Logistic regression, the only significant associations were 
cough and haemoptysis. Most of the PTB patients were came with opacities with or 
without cavitation of abnormal radiological findings. Meanwhile the common site for 
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ETB was miliary TB with the risk factors for this type of TB were men, intravascular 
drug users and specific racial origin (Nissapatorn et al., 2005).  
The study also found that lower CD4 count was more potential to develop ETB 
rather than PTB. The duration of treatment to success was longer in ETB (nine 
months) compared to PTB (six months). 
The risk factors that associated with TB diagnosis were younger age, lower recent 
CD4 T cells count, duration of antiretroviral therapy and living in high TB burden 
countries. Patients aged more than 40 years old had significantly lower rate of TB 
diagnosis than that of patients aged 30 or younger (adjusted Hazard ratio 
(HR)=0.47;95%CI: 0.28, 0.79). A higher CD4 T cells count was associated with a 
significantly lower rate of TB diagnosis. Compared to patients who were not 
receiving antiretroviral therapy, there was a significant increase in the rate of TB 
diagnosis within 90 days after initiating therapy (adjusted HR=2.52, 95% CI: 1.31, 
4.84). The rate of TB diagnosis was significantly lower among patients living in 
countries with low/intermediate TB burden (adjusted HR=0.28, 95% CI: 0.17, 0.45) 
(Zhou et al., 2009).  
2.4 Associated Factors of ATT Compliance  
ATT compliance or adherence to the treatment may be influenced by many factors. 
This situation can be particularly challenging since the duration of treatment take a 
long period (usually six months or longer), requirement of combination therapy, and 
side effects may be unpleasant. Furthermore, when patients experience rapid 
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improvement in symptoms, the decision to discontinue the treatment may take a 
place even though the treatment is not complete yet (Reichman & Lardizabal, 2013).  
Some factors such as the distance to health facilities (Castelnuovo, 2010) which 
consumes time , transportation, financial status (Neves, 2010) and social support also 
influence patients to comply with the treatment. 
Besides that, the support and counseling session from the health care staff may 
motivate patients to adherence to the treatment. The staff also can provide the 
knowledge of the disease and the important of the treatment to the patients (Neves, 
2010). 
Directly observed therapy is a strategy to improve the treatment adherence. However, 
from the existing trials, DOTS did not provide a solution to poor adherence in TB 
treatment. Given the large resource and cost implications of DOTS, policy makers 
might want to reconsider the strategy that depends on direct observation (Karumbi & 
Garner, 2015) 
Anaam et. al. (2013) had suggested that reducing travelling and waiting times for TB 
patients may improve compliance rates by expansion of directly observed treatment 
short-course near to patients’ homes and involving additional staff. 
2.5 Associated Factors of ATT Outcomes 
Compliance to a tuberculosis treatment  may give a positive impact on anti 
tuberculosis treatment success. Most of the studies divided the treatment into two 
categories; success and unsuccess. Patients who cured or completed the treatment 
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was grouped into success group. Meanwhile, for patients who failed in treatment, 
defaulted, transfer or died was located in unsuccess group (Okanurak et. al., 2008; 
Shaffer et. al.,2012; Ismail & Bulgiba, 2013a) 
Ismail & Bulgiba (2013a) study which was claimed as the first report in Malaysia on 
identifying the risk factors of unsuccessful TB treatment outcome in HIV infected 
patient had identified four associated factors of unsuccessful in TB treatment after 
twelve months initiated the TB treatment among TB/HIV co-infected patients. The 
factors were intravenous drug users (IVDU), not receiving anti-retroviral therapy, 
lymphadenopathy and low in serum albumin. 
A cohort study which was conducted at Bangkok, Thailand had predicted the factors 
associated with successful in TB treatment. The predictor factors were female, 
monthly wage income patients, patients with moderate or high levels of knowledge 
in TB and its treatment and patients with adverse effects (Okanurak et. al., 2008).  
In South India, Vijay et. al. (2011) had determined the factors associated with 
unsuccessful in TB treatment in TB/HIV co-infected patients such as pulmonary TB, 
retreatment cases and non initiation of antiretroviral therapy (ART). Meanwhile in 
North India, the factors of unsuccessful in TB treatment were retreatment cases and 
CD4 cell count less than 200cell/µL (Sharma et. al., 2014). 
2.6 Survival and Predictors Factors of mortality in TB/HIV co-infection 
A negative TB tuberculin test and low CD4 count were associated with an increase in 
mortality, implying that the extent to which immune function is suppressed is of the 
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utmost importance in the prediction of the survival rate of patients with TB/HIV co-
infection (Serrat et al., 1998; Jiang et al., 2008). 
Survival in a similar group of those who never had TB but were matched for CD4
+
 
T-cell count showed that at each level of CD4
+
 T-cell count, survival was worse for 
patients who had TB. It appears that TB accelerates the natural history of HIV 
infection and leads to earlier death. 
Klautau & Kuschnaroff (2005) were observed lower CD4
+
 T-cell mean values in 
cases of treatment failure and death. There was a significant correlation between the 
CD4
+
 T-cell values and the TB outcome at six time points of the study (0 months, 2 
months, 4 months, 6 months, 10 months and 15 months). Meanwhile there was a 
significant correlation between CD8
+
 T-cell values and TB outcome at the first and 
third assessment point of the study. A correlation between HIV viral load values and 
the response to the treatment was also observed at the end of the treatment. The study 
also found that there was a possible relationship between TB outcome and laboratory 
parameters, lower mean values of haemoglobin, haematocrit, platelet and leucocytes 
among the cases of treatment failure. As a conclusion, Pancytopenia and low levels 
of CD4
+
 T-cell and CD8
+
 T-cell  at the initial time point of the study were correlated 
with an unfavourable outcome of TB and can be considered as a potential predictor 
factors. 
Tseng et al. (2009) done a study on “effect of free treatment and surveillance on 
HIV- infected persons who have tuberculosis, Taiwan, 1993-2006” has  reported that 
the  surveillance reporting and management and with the availability of free HAART 
has increased the survival rates of persons co-infected with HIV and TB.  
